Medication info
Baropozitone 5/160 mg

Baropozitone 5/160 mg

Prescription medicationTabletOral
Ingredient · strength
Valsartan›160mg / 1 tabletAmlodipine Besylate›6.94mg / 1 tablet
Manufacturer / importer
Daehwa Pharmaceutical Co., Ltd.
Appearance
Dark yellow rectangular film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 201308584 · Approved 2013.07.31 · Insurance code 645604260

Summary

Main use
Treatment of essential hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
The recommended dose is 1 tablet once daily, taken with water, with or without food. It is recommended that the tablet be taken at the same time each day, if possible (e.g., in the morning). It is recommended that the dose be adjusted using the individual components (amlodipine or valsartan) before administering this medicine. However, if blood pressure is not controlled with monotherapy using the individual components, switching directly to this medicine may be considered as follows. ㆍ 5/80 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 80 mg monotherapy. ㆍ 5/160 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 160 mg monotherapy. ㆍ 10/160 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or valsartan 160 mg monotherapy, or with 5/160 mg. Patients taking valsartan and amlodipine concomitantly may switch to this medicine (a combination product containing the same amount of each active ingredient) for convenience. Patients with renal impairment: No dose adjustment is required in patients with mild to moderate renal impairment (creatinine clearance 10mL/min or greater). This medicine should not be administered to patients with severe renal impairment (creatinine clearance less than 10mL/min) or patients on dialysis. Monitoring of potassium levels and creatinine is recommended in patients with moderate renal impairment. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, the daily dose of valsartan should not exceed 80mg. This medicine should not be administered to patients with severe hepatic impairment, biliary cirrhosis, or biliary obstruction or cholestasis. Elderly patients aged 65 years or older: Caution should be exercised when increasing the dose.
Child dose
The safety and efficacy have not been established in pediatric patients under 18 years of age; therefore, use of this medicine is not recommended.

Ingredients

Manufacturer
Daehwa Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with monotherapy

  • Essential hypertension
View approved original text

This medication is used to effectively lower blood pressure in patients with essential hypertension who have difficulty controlling blood pressure with monotherapy using amlodipine or valsartan.

How to take

Adult dose

The recommended dose is 1 tablet once daily, taken with water, with or without food. It is recommended that the tablet be taken at the same time each day, if possible (e.g., in the morning). It is recommended that the dose be adjusted using the individual components (amlodipine or valsartan) before administering this medicine. However, if blood pressure is not controlled with monotherapy using the individual components, switching directly to this medicine may be considered as follows. ㆍ 5/80 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 80 mg monotherapy. ㆍ 5/160 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 160 mg monotherapy. ㆍ 10/160 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or valsartan 160 mg monotherapy, or with 5/160 mg. Patients taking valsartan and amlodipine concomitantly may switch to this medicine (a combination product containing the same amount of each active ingredient) for convenience. Patients with renal impairment: No dose adjustment is required in patients with mild to moderate renal impairment (creatinine clearance 10mL/min or greater). This medicine should not be administered to patients with severe renal impairment (creatinine clearance less than 10mL/min) or patients on dialysis. Monitoring of potassium levels and creatinine is recommended in patients with moderate renal impairment. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, the daily dose of valsartan should not exceed 80mg. This medicine should not be administered to patients with severe hepatic impairment, biliary cirrhosis, or biliary obstruction or cholestasis. Elderly patients aged 65 years or older: Caution should be exercised when increasing the dose.

Child dose

The safety and efficacy have not been established in pediatric patients under 18 years of age; therefore, use of this medicine is not recommended.

Precautions

This medication can cause serious harm to the fetus when taken during pregnancy, especially in the second and third trimesters, so it must be discontinued immediately upon confirmation of pregnancy. This medication should not be used by women who are allergic to the active ingredients, pregnant, breastfeeding, or patients with severe kidney or liver dysfunction. Patients with low sodium or fluid may experience hypotension; thus, their condition should be corrected before taking this medication, and careful monitoring is required during administration. Patients with high potassium levels should be cautious when taking this medication together with potassium supplements or medications that can increase potassium levels, and potassium levels should be monitored regularly. Patients with kidney problems or those who have undergone kidney transplantation should closely monitor kidney function changes when using this medication. If symptoms of angioedema occur, the medication should be discontinued immediately, and re-administration should be avoided. Patients with heart failure or those recovering from myocardial infarction require careful monitoring, including evaluation of kidney function. Dizziness or fatigue may occur when driving or operating machinery, so caution is advised. This medication may interact with other antihypertensives, potassium supplements, diuretics, and non-steroidal anti-inflammatory drugs, so it is essential to consult a physician or pharmacist about concurrent use of any other medications. In case of overdose, symptoms such as hypotension, dizziness, and tachycardia may occur; thus, if any abnormal symptoms arise, a healthcare facility should be visited immediately. This medication is not recommended for patients under 18 years of age as its safety and effectiveness have not been sufficiently established. Elderly patients can be administered similar dosages as general adults, but careful monitoring is necessary.

Side effects

nasopharyngitis, influenza, hypersensitivity, visual impairment, anxiety, headache, dizziness, drowsiness, orthostatic dizziness, paresthesia, vertigo, tinnitus, tachycardia, palpitations, syncope, orthostatic hypotension, hypotension, cough, pharyngeal and laryngeal pain, diarrhea, nausea, abdominal pain, constipation, dry mouth, rash, erythema, hyperhidrosis, rash, pruritus, joint swelling, low back pain, arthritis, muscle spasm, lethargy, frequency of urination, polyuria, erectile dysfunction, edema, anasarca, facial edema, peripheral edema, fatigue, flushing, asthenia, facial flushing, decreased hemoglobin, decreased hematocrit, neutropenia, thrombocytopenia, hypersensitivity including serum sickness, increased serum potassium, vasculitis, elevated liver function tests, angioedema, myalgia, renal failure, kidney damage, increased serum creatinine, insomnia, decreased libido, pharyngitis, rhinitis, sinusitis, upper respiratory tract infection, viral infection, intestinal vascular edema, diplopia, thrombocytopenia, leukopenia, allergic reaction, hyperglycemia, insomnia, mood changes, tremors, sensory decrease, taste abnormalities, peripheral neuropathy, excessive muscle tension, arrhythmia, bradycardia, atrial fibrillation, ventricular tachycardia, myocardial infarction, vasculitis, dyspnea, rhinitis, vomiting, dyspepsia, pancreatitis, gastritis, gingival hyperplasia, hepatitis, jaundice, alopecia, purpura, skin depigmentation, photosensitivity reaction, angioedema, urticaria, erythema multiforme, Stevens-Johnson syndrome, myalgia, dysuria, nocturnal enuresis, gynecomastia, pain, malaise, chest pain, weight loss, weight gain, elevated liver enzymes, chest pain, weight gain, arthralgia, skeletal pain, rhabdomyolysis, gingival hyperplasia, gastritis, neuroirritability, sensory decrease, Stevens-Johnson syndrome

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture. It is important to maintain a storage temperature between 1 to 30 degrees Celsius at room temperature. Proper storage ensures the medication's effectiveness and safety for a longer period.

Appearance and packaging

Appearance

Dark yellow rectangular film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.